

DAFTAR PUSTAKA

1. Kim HY, Kwon JW, Seo J, Song YH, Kim BJ, Yu J, et al. Bronchiectasis in children: 10-year experience at a single institution. *Allergy, Asthma Immunol Res.* 2010;3:39–45.
2. Rahajoe, N N, Supriyanto B, Setyanto, D B. *Respirologi Anak*. 2008;
3. Banjar H, Ventura W. A long-term follow-up study of childhood bronchiectasis. *Bahrain Med Bull* [Internet]. 2006;28:64–8.
4. Kim HY, Kwon JW, Seo J, Song YH, Kim BJ, Yu J, et al. Bronchiectasis in children: 10-year experience at a single institution. *Allergy, Asthma Immunol Res.* 2010;3:39–45.
5. Kapur N, Karadag B. Differences and similarities in non-cystic fibrosis bronchiectasis between developing and affluent countries. *Paediatr Respir Rev* [Internet]. 2011;12:91–6.
6. Kapur N, Masters IB, Morris PS, Galligan J, Ware R, Chang AB. Defining pulmonary exacerbation in children with non-cystic fibrosis bronchiectasis. *Pediatr Pulmonol.* 2012;47:68–75.
7. Brower KS, Del Vecchio MT, Aronoff SC. The etiologies of non-CF bronchiectasis in childhood: A systematic review of 989 subjects. *BMC Pediatr.* 2014;14.
8. King PT. The pathophysiology of bronchiectasis. *Int J Chron Obstruct Pulmon Dis.* 2009;4:411–9.
9. Pasteur MC, Bilton D, Hill AT. British thoracic society guideline for non-CF bronchiectasis. *Thorax.* 2010;65.
10. Sethi GR, Batra V. *Bronchiectasis : Causes and Management*.
11. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory Effects of Macrolide Antibiotics – Part 2: Advantages and Disadvantages of Long-Term, Low-Dose Macrolide Therapy. *Respiration.* 2010;81:75–87.
12. Chang AB, Bush A, Grimwood K. Bronchiectasis in children: diagnosis and treatment. *Lancet* [Internet]. 2018;392:866–79.
13. Kelly C, Jd C, Crossingham I, Relph N, Lm F, Dj E, et al. Macrolide antibiotics for bronchiectasis (Review) SUMMARY OF FINDINGS FOR THE MAIN COMPARISON. 2018;

14. Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: A systematic review. *Eur Respir J*. 2014;44:382–93.
15. Sehitogullari A, Bilici S, Sayir F, Cobanoglu U, Kahraman A. A long-term study assessing the factors influencing survival and morbidity in the surgical management of bronchiectasis. *J Cardiothorac Surg*. 2011;6:3–8.
16. Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M, et al. Mortality in bronchiectasis: A long-term study assessing the factors influencing survival. *Eur Respir J*. 2009;34:843–9.
17. Onen ZP, Eris Gulbay B, Sen E, Akkoca Yildiz Ö, Saryal S, Acican T, et al. Analysis of the factors related to mortality in patients with bronchiectasis. *Respir Med*. 2007;101:1390–7.
18. Hanny R, Walidi N. Pelayanan Kesehatan Anak di Rumah Sakit. Pedoman bagi Rumah Sakit Rujukan Tingkat Pertama di Kabupaten/Kota. *WHO Indones*. 2009;1:434.
19. Walson JL, Berkley JA. The impact of malnutrition on childhood infections. *Curr Opin Infect Dis*. 2018;31:231–6.
20. Twiss J, Stewart AW, Byrnes CA. Longitudinal pulmonary function of childhood bronchiectasis and comparison with cystic fibrosis. *Thorax*. 2006;61:414–8.
21. Varni JW, Planning U. *Pediatric Quality of Life Inventory™ Peds QL*.
22. Karadag B, Karakoc F, Ersu R, Kut A, Bakac S, Dagli E. Non-cystic-fibrosis bronchiectasis in children: A persisting problem in developing countries. *Respiration*. 2005;72:233–8.
23. Cole SZ, Lanham JS. Failure to thrive: An update. *Am Fam Physician*. 2011;83:829–34.
24. Qi Q, Li T, Li JC, Li Y. Association of body mass index with disease severity and prognosis in patients with non-cystic fibrosis bronchiectasis. *Brazilian J Med Biol Res* [Internet]. 2015;48:715–24.
25. Bilan N, Aghakhani M, Niafar F. Factors Affecting the Outcome of Bronchiectasis in Pediatric Patients. 2:377–89.
26. Goeminne PC, Nawrot TS, Ruttens D, Seys S, Dupont LJ. Mortality in non-cystic fibrosis bronchiectasis: A prospective cohort analysis. *Respir Med* [Internet]. 2014;108:287–96.
27. Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M, et al. Mortality in bronchiectasis: A long-term study assessing the factors influencing survival. *Eur Respir J*. 2009;34:843–9.

28. Bastardo CM, Sonnappa S, Stanojevic S, Navarro A, Lopez PM, Jaffe A, et al. Non-cystic fibrosis bronchiectasis in childhood: Longitudinal growth and lung function. *Thorax*. 2009;64:246–51.
29. Scullion J, Holmes S. Diagnosis and management of patients with bronchiectasis. *Nurs Stand*. 2013;27:49–55.
30. Wroblewska L, Kitada T, Endo K, Siciliano V, Stillo B, Saito H, et al. HHS Public Access. 2016;33:839–41.
31. Bossone E, D’Andrea A, D’Alto M, Citro R, Argiento P, Ferrara F, et al. Echocardiography in pulmonary arterial hypertension: From diagnosis to prognosis. *J Am Soc Echocardiogr* [Internet]. 2013;26:1–14.
32. Li H, Liu DH, Chen LL, Zhao Q, Yu YZ, Ding JJ, et al. Meta-Analysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases. *Antimicrob Agents Chemother*. 2014;58:511–7.
33. Redondo M, Ferri S, Chalmers J. Exacerbations of bronchiectasis in adults. *Community Acquir Infect*. 2016;3:43.
34. Pasteur MC, Bilton D, Hill AT. British thoracic society guideline for non-CF bronchiectasis. *Thorax* [Internet]. 2010;65:577.
35. Grant LR, Hammitt LL, Murdoch DR, O’Brien KL, Scott JA. Procedures for collection of induced sputum specimens from children. *Clin Infect Dis*. 2012;54.
36. Altenburg J, De Graaff CS, Van Der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics - Part 2: Advantages and disadvantages of long-term, low-dose macrolide therapy. *Respiration*. 2010;81:75–87.
37. Ashurst J V, Dawson A. Klebsiella Pneumonia [Internet]. Finlandia: Statpearls publishing LLC; 2019. 8(30).
38. Doern CD, Burnham CAD. It’s not easy being green: The viridans group streptococci, with a focus on pediatric clinical manifestations. *J Clin Microbiol*. 2010;48:3829–35.